RT Journal Article
SR Electronic
T1 “Epidemiological profile of patients with stage 5 chronic kidney disease on dialysis with Covid 19 infection in a Public Hospital-Perú”
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.30.21264132
DO 10.1101/2021.09.30.21264132
A1 Yanissa Venegas-Justiniano
A1 César Loza-Munarriz
A1 Abdías Hurtado-Aréstegui
YR 2021
UL http://medrxiv.org/content/early/2021/10/01/2021.09.30.21264132.abstract
AB Introduction Chronic kidney disease (CKD) in Covid 19 is relevant, however, there are few descriptions and fewer in Peru. Our goal was to describe the epidemiological profile and the factors related to mortality and survival of patients with stage 5 (CKD) on chronic dialysis hospitalized for Covid-19 in a public hospital.Methods Retrospective case series. Patients with stage 5 CKD, older than 18 years, hospitalized for Covid-19 infection were included. The primary data source was medical records. The clinical and epidemiological profile of the study sample and the factors related to mortality and survival are described.Results 105 medical records of patients with CKD 5 were evaluated. 57 (54,29%) were male, with a mean age of 58,59 ± 14,3 years. 84 (80%) patients survived and 21 (20%) died. The main cause of admission to hospitalization was respiratory failure in (80) 76,2%. The hospital stay was 11,76 ± 7,8 days. In the bivariate analysis: the increase in leukocytes, D dimer, ferritin, CRP, LDH and the decrease in lymphocytes, pH, bicarbonate and PaO2/FiO2 were related to mortality. In the multivariate analysis, only CRP> 10 mg/dl [HR: 10.72 (95% CI 1,4-81,58)] and a PaO2/FiO2 ≤ 150 mmHg [HR: 44,40 (95% CI 5,86-336,06)] they were factors related to poor survival.Conclusions CRP levels> 10mg/dl and PaO2/FiO2 ≤ 150 mmHg are the main factors related to mortality and poor survival in patients with stage 5 CKD hospitalized for Covid-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any type of financial support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Ethics and Research Committee of the Cayetano Heredia Peruvian University approved the study under the number 039-01-21 and since it is a retrospective study, it is exempt from informed consent. NOTE: At the end of the manuscript, the document of The Institutional Ethics and Research CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the investigator's database in the Nephrology Unit.